Your browser doesn't support javascript.
loading
Lead (Pb) in Alzheimer's Dementia: A Systematic Review of Human Case- Control Studies.
Brown, Eric E; Shah, Parita; Pollock, Bruce G; Gerretsen, Philip; Graff-Guerrero, Ariel.
Afiliação
  • Brown EE; Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
  • Shah P; Institute of Medical Science, University of Toronto, Toronto, ON, Canada.
  • Pollock BG; Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada.
  • Gerretsen P; Institute of Medical Science, University of Toronto, Toronto, ON, Canada.
  • Graff-Guerrero A; Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada.
Curr Alzheimer Res ; 16(4): 353-361, 2019.
Article em En | MEDLINE | ID: mdl-30854970
ABSTRACT

BACKGROUND:

Alzheimer's Dementia (AD) has a complex pathophysiology that is incompletely understood. Chronic, low-level environmental lead (Pb) exposure is associated with cognitive impairment, hypertension and mortality, and has been proposed as a potential cause of AD.

OBJECTIVE:

We aimed to review the literature to clarify the potential role of Pb in AD and to guide future research.

METHODS:

Through a series of systematic reviews, we identified case-control studies comparing AD to controls on 6 measures of Pb exposure or accumulation blood, bone, cerebrospinal fluid, hair/nail, postmortem pathology, and urine. We completed meta-analyses where possible.

RESULTS:

The number of identified case-control studies of AD, by measurement method, was 15 by blood, 0 by bone, 5 by Cerebrospinal Fluid (CSF), 3 by hair/nail, 3 by postmortem, and 1 by urine. Two meta-analyses were possible for 7 studies reporting whole blood Pb and for 8 studies of serum Pb. Both were negative. The largest study of CSF Pb showed lower levels in AD. Similarly, lower hair Pb levels were found in AD.

CONCLUSION:

The available case-control studies are insufficient to draw conclusions on the role of Pb in AD. Most methods do not address long-term or early-life exposure. The preferred measure of chronic Pb is in bone, which has not been utilized in case-control AD studies. Future research should measure bone Pb in AD, together with other biomarkers, such as amyloid and tau imaging, and markers of cerebrovascular pathology.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Alzheimer / Chumbo Tipo de estudo: Observational_studies / Risk_factors_studies / Systematic_reviews Limite: Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Alzheimer / Chumbo Tipo de estudo: Observational_studies / Risk_factors_studies / Systematic_reviews Limite: Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article